PARSIPPANY, N.J. — October 2, 2026
Teva Pharmaceuticals announced that the Journal of Child Neurology has published a comprehensive review examining the role of dopamine signaling in Tourette syndrome and the therapeutic potential of ecopipam, an investigational selective dopamine D1 receptor antagonist being developed for pediatric patients. The review examines how dopamine pathways may contribute to tic generation and summarizes clinical evidence from the ecopipam development program, including findings indicating reduced tic severity, sustained treatment benefit and lower risk of relapse in pediatric patients. Ecopipam is designed to selectively target D1 receptors in the brain’s direct motor pathway, providing a differentiated mechanism from conventional D2 receptor-targeting antipsychotic therapies. Teva said the publication further supports continued investigation of D1 receptor antagonism as a potential non-antipsychotic treatment approach for children and adolescents with Tourette syndrome.
Ecopipam Targets D1 Dopamine Signaling
The review describes the biological rationale for selectively targeting dopamine D1 receptors in Tourette syndrome. Tourette syndrome is a chronic neurodevelopmental disorder characterized by involuntary motor and vocal tics that generally begin during childhood. Elevated dopaminergic activity in the basal ganglia has been proposed as one contributor to tic expression. D1 receptors are primarily expressed by neurons involved in the brain’s direct motor pathway, and ecopipam is designed to block excessive dopamine signaling through this pathway. This differs from traditional antipsychotic therapies that primarily target D2 receptors associated with the indirect motor pathway. Teva said this mechanistic distinction could potentially provide an alternative approach to reducing tic severity while avoiding some complications associated with D2-targeting medicines. The company is studying ecopipam as a potential first-in-class D1 receptor antagonist for Tourette syndrome in pediatric patients.
Clinical Data Show Sustained Tic Control
Clinical evidence summarized in the review includes findings from Phase 2b and Phase 3 studies of ecopipam in pediatric and adult participants. In the Phase 3 D1AMOND trial, which enrolled 216 participants, continued ecopipam treatment reduced the risk of tic relapse by 50% compared with placebo in pediatric participants following treatment stabilization. The reported hazard ratio was 0.5, with a P value of 0.008. Earlier Phase 2b results and a 12-month open-label extension also supported sustained reductions in tic severity over time. Across clinical trials, commonly reported adverse events included somnolence, headache, insomnia, fatigue and anxiety. The review highlighted the absence of clinically relevant weight gain, adverse metabolic effects or drug-induced movement disorders in the reported ecopipam clinical experience. The potential relevance of this tolerability profile is notable because treatment persistence can be challenging with existing D2 receptor antagonists, with real-world discontinuation rates reported at 61.2% by three months and 82.1% by 18 months.
Advertisement
Teva Advances Pediatric Tourette Program
Teva is advancing ecopipam as an investigational treatment specifically for pediatric Tourette syndrome, with the company having received FDA Priority Review and Orphan Drug designation for the candidate. The D1AMOND Phase 2b trial evaluated 153 pediatric participants in a randomized, double-blind, placebo-controlled study across North America and Europe, while its open-label extension followed participants for up to 12 months to assess longer-term safety and tolerability. The subsequent Phase 3 D1AMOND study used a randomized-withdrawal design to evaluate maintenance of efficacy among responders, although the development program included both pediatric and adult participants, the NDA and intended indication are focused exclusively on pediatric patients. Ecopipam remains investigational and has not been approved by regulatory authorities for Tourette syndrome. With the Journal of Child Neurology review consolidating mechanistic and clinical evidence supporting selective D1 receptor antagonism, Teva is continuing development of an approach intended to address tic severity while potentially offering a differentiated safety and tolerability profile compared with conventional dopamine D2-targeting therapies.
Source: Teva Pharmaceuticals, press release
